Twice-weekly portable electrocardiogram screening
Twice-weekly portable electrocardiogram screening has been studied in 1 paper since 2023: 1 trial in people. The newest paper, May 3, 2023: “Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study”.
1 paper studies it6 findingsUpdated
See all 1 papers on twice-weekly portable electrocardiogram screening
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Over the full period of follow-up, although detection of AF was 38.7% greater in the iECG group compared with RC, this difference was not statistically significant.”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: AliveCor and 1 more
- Human trial1
Studies in people
1 study gave twice-weekly portable electrocardiogram screening to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on atrial fibrillation+38.7% no change: Has no effect on stroke no change: Has no effect on mortality | Randomized trial4.2 years | 997 people53.3% femalemean age 72.6 ± 5.4 yearsPatients over 65 years with a CHADS-VASc score ≥ 2, without a known diagnosis of AF, known contraindication to anticoagulation or permanent cardiac pacing implantation | European heart journal open, May 3, 2023 |
What did studies of twice-weekly portable electrocardiogram screening find?
3Studies of twice-weekly portable electrocardiogram screening measured 3 outcomes: mortality, stroke and atrial fibrillation.
Mortality
no changein humans1HR 1.07
1 study
Mortality
no changein humans1HR 1.07
Twice-weekly portable electrocardiogram screening showed no clear effect on mortality in humans.
“There was no difference in the number of deaths, strokes, or TIA between the two groups.”
Human trial4.2 yearsn = 997
European heart journal open
Twice-weekly portable electrocardiogram screening showed no clear effect on mortality in humans (HR 1.07, 95% CI 0.66-1.73).
“HR 1.07, 95% CI 0.66-1.73”
Human trialmedian 4.2-year
European heart journal open
Stroke
no changein humans1HR 0.92
1 study
Stroke
no changein humans1HR 0.92
Twice-weekly portable electrocardiogram screening showed no clear effect on stroke in humans.
“There was no difference in the number of deaths, strokes, or TIA between the two groups.”
Human trial4.2 yearsn = 997
European heart journal open
Twice-weekly portable electrocardiogram screening showed no clear effect on stroke in humans (HR 0.92, 95% CI 0.54-1.54).
“No differences were seen in the number of strokes/systemic embolisms or deaths between the two groups (HR 0.92, 95% CI 0.54-1.54”
Human trialmedian 4.2-year
European heart journal open
Atrial fibrillation
no changein humans1+39%
1 study
Atrial fibrillation
no changein humans1+39%
Twice-weekly portable electrocardiogram screening showed no clear effect on atrial fibrillation in humans (+38.7%).
“Over the full period of follow-up, although detection of AF was 38.7% greater in the iECG group compared with RC, this difference was not statistically significant.”
Human trial4.2 yearsn = 997
European heart journal open
What is twice-weekly portable electrocardiogram screening linked with?
1Studies link twice-weekly portable electrocardiogram screening with acute coronary syndrome.
Acute coronary syndrome
downin humans1
1 study
Acute coronary syndrome
downin humans1
Twice-weekly portable electrocardiogram screening lowers the risk of acute coronary syndrome in humans (10 vs. 21).
“Participants in the iECG care group were less likely to have an acute coronary syndrome event during the follow-up period than in the RC group (10 vs. 21, P = 0.044; ).”
Human trial4.2 yearsn = 997
European heart journal open